Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Operating activities:
Net loss	$ (18,838,000)	$ (516,000)
Adjustments required to reconcile net income to net cash used in operating activities:
Change in fair value of derivative and warrant liabilities	(4,538,000)	(9,940,000)
Impairment charges	9,547,000
Stock-based compensation	1,995,000	483,000
Costs related to equity offerings, and other	756,000	213,000
Deferred taxes	(556,000)	(73,000)
Noncash interest expense	6,000
Amortization of patents	31,000	31,000
Depreciation expenses	338,000	299,000
Gain on re-valuation of liquidated damages liability		(120,000)
Changes in operating assets and liabilities net of acquisitions:
Accounts receivable, net	100,000	(25,000)
Accounts payable, accrued expenses, deferred revenue and other	298,000	(123,543)
Accrued compensation	167,000	172,543
Prepaid expenses and other current assets	105,000	(182,000)
Net cash used in operating activities	(10,589,000)	(9,781,000)
Investing activities:
Purchases of property and equipment	(279,000)	(210,000)
Net cash used in investing activities	(279,000)	(210,000)
Financing activities:
Proceeds from warrant exercises		396,000
Costs of Series B redeemable convertible preferred stock conversion to common stock	(173,000)
Dividend payments	(80,000)
Proceeds from equity offerings, net	7,566,000	12,384,000
Proceeds from stock issuance under employee stock purchase plan	13,000
Principal payment on note payable and other financing liability	(117,000)
Net cash provided by financing activities	7,209,000	12,780,000
Net (decrease) increase in cash and cash equivalents	(3,659,000)	2,789,000
Cash and cash equivalents, beginning of period	9,370,000	6,581,000
Cash and cash equivalents, end of period	5,711,000	9,370,000
Supplemental schedule of non-cash financing activities:
Accretion of Series B redeemable convertible preferred stock	1,858,000	10,278,000
Fair value of warrant liability upon issuance	4,745,000	$ 4,210,000
Unpaid offering costs	$ 69,000